Live salmonella vaccine having an increased stability
OwnerKlaus Lindeinventor
Life of this patent
Estimating the term…
Abstract
A live Salmonella vaccine having an increased stability is disclosed. Further, immunization methods of a host such as chickens against Salmonella diseases are carried out by the use of the vaccine. The vaccine may be administered orally or parenterally and includes one or more of the live vaccines disclosed herein. The live vaccine is produced from one or more live vaccine strains with metabolic drift attenuation via an increased generation time. The vaccine is an immunogenic, stable and single or multiple marker live vaccine strain with or without envelope mutation; and the live vaccine is a suppressor mutant of an original live vaccine strain still having the attenuation marker(s) of the original live vaccine strain but a shortened generation time and having macrolide tolerance.
Claims3
A live Salmonella vaccine comprising one or more suppressor mutant Salmonella strains that are derived from original live metabolic drift attenuated vaccine strains, said mutant Salmonella strains having an increased stability in at least one attenuating metabolic drift marker and an attenuation level adapted to the sensitivity of a host species, wherein each mutant Salmonella strain has a shortened generation time which has been shortened from about 31-32 minutes to .ltoreq.27 minutes and/or an increased macrolide tolerance whereby the minimum inhibitory concentration (MIC) toward erythromycin increases from .ltoreq.5 ug/mL to .gtoreq.20 ug/mL, in comparison to the original live vaccine strains from which said mutant Salmonella strains were derived.
Dependencies are inferred from the claim text.